The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The End of the Beginning: COVID-19 Vaccines & Other Conundrums

The End of the Beginning: COVID-19 Vaccines & Other Conundrums

December 9, 2020 • By Philip Seo, MD, MHS

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Why the lower dose may be more effective than the higher dose is not clear. The most logical answer is that it is not. The difference may be the result of a statistical fluke, and it is possible that if the trial had continued to enroll patients, the difference may have eventually disappeared. If the difference is real, it might be that the higher dose stimulated a more robust response against the adenoviral vector itself, which prevented it from reaching its target.6

You Might Also Like
  • ACR Convergence 2020: Progress Toward COVID-19 Vaccines
  • COVID-19 Immunization Day: It Won’t Be Long Before We Can Hug Again
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
Also By This Author
  • Thinking Big, Thinking Small

Even if the AstraZeneca vaccine is somewhat less effective than its brethren, it is hard to call it an inferior product. The Pfizer vaccine is a prima donna whose exacting requirements need to be met if we want her to perform: The vaccine needs to be stored at -70°C. Each vial contains five doses of the vaccine; each vial must be thawed, split and administered in short order to be effective.7

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The AstraZeneca vaccine is a working grunt. Refrigerated, it is stable for a month; frozen at -20°C, it is stable for six months. Cheap to manufacture, easy to transport, it’s no wonder that many countries have turned to the AstraZeneca vaccine for salvation.8

Remembering that vaccine development in the past has taken years, or even decades of work, it is truly incredible that we now have three vaccines against a virus that none of us had heard of a year ago, with even more options on the way. But who goes first?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Remembering that vaccine development in the past has taken years, or even decades of work, it is truly incredible that we now have three vaccines against a virus that none of us had heard of a year ago, with even more options on the way. But who goes first?

Waiting Your Turn
Pity the poor souls who populate the Advisory Committee on Immunization Practices (ACIP); they could have never suspected their sleepy committee might be the center of so much attention. Established in 1964 by the U.S. Surgeon General, the ACIP is a committee within the Centers for Disease Control and Prevention that is responsible for making recommendations regarding vaccine-preventable diseases.9 The question of who should be vaccinated first falls squarely within their mandate.

On Dec. 1, the ACIP suggested a phased allocation of COVID-19 vaccine supplies.10 Not surprisingly, the committee suggests that first dibs should go to healthcare personnel and long-term healthcare residents. Together, these groups represent approximately 24 million people. To put this in perspective, by the end of 2020, Pfizer and Moderna will have supplied the U.S. with enough vaccine to vaccinate only 22.5 million people.11 And that’s just phase 1a.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Rheuminations Tagged With: COVID-19

You Might Also Like:
  • ACR Convergence 2020: Progress Toward COVID-19 Vaccines
  • COVID-19 Immunization Day: It Won’t Be Long Before We Can Hug Again
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • Early Lessons from the COVID-19 Pandemic: A Q&A with Chris Phillips, MD

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.